Anzeige
❌
Mehr »
Freitag, 20.11.2026 - Börsentäglich über 12.000 News
Rund 40 Mio. USD Staatsaufträge bis Juni 2029 gebucht: Jetzt zählt die Marge!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
AM

WKN: A11664 | ISIN: US03209R1032 | Ticker: 29A
Tradegate
19.11.26 | 19:50
25,510 Euro
-0,51 % -0,130
1-Jahres-Chart
AMPHASTAR PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
AMPHASTAR PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
25,53025,73019.11.
25,39025,89019.11.

Aktuelle News zur AMPHASTAR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
05.11.Amphastar Pharmaceuticals Non-GAAP EPS of $1.14 beats by $0.28, revenue of $207.6M beats by $10.1M1
05.11.Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026109Net revenues of $207.6 million for the three months ended September 30, 2026GAAP net income of $37.8 million, or $0.87 per share, for the third quarterAdjusted non-GAAP net income of $49.3 million,...
► Artikel lesen
AMPHASTAR Aktie jetzt für 0€ handeln
05.11.Amphastar Pharmaceuticals, Inc. - 10-Q, Quarterly Report-
08.09.Amphastar setzt für Wachstum auf Baqsimi und die Entwicklungspipeline4
07.08.Amphastar anticipates $2M-$3M per quarter IMS remediation costs while maintaining mid-single digit to high single-digit 2026 sales growth1
06.08.Amphastar Pharmaceuticals Non-GAAP EPS of $0.91 beats by $0.30, revenue of $183.9M beats by $3.98M2
06.08.Amphastar Pharmaceuticals, Inc. - 10-Q, Quarterly Report1
06.08.Amphastar Pharmaceuticals, Inc. - 8-K, Current Report3
06.08.Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026247Net revenues of $183.9 million for the three months ended June 30, 2026 GAAP net income of $30.3 million, or $0.67 per share, for the second quarter Adjusted...
► Artikel lesen
08.07.Amphastar unit gets FDA warning letter over manufacturing violations13
08.07.Amphastar Pharmaceuticals, Inc. - 8-K, Current Report-
03.06.Amphastar Pharmaceuticals, Inc. - 8-K, Current Report1
27.05.Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare Conference533RANCHO CUCAMONGA, CA / ACCESS Newswire / May 27, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will...
► Artikel lesen
07.05.Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026671Net revenues of $171.2 million for the three months ended March 31, 2026GAAP net income of $6.4 million, or $0.14 per share, for the first quarterAdjusted non-GAAP net income of $19.5 million, or $0.42...
► Artikel lesen
06.05.Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Present at the 2026 Bank of America Health Care Conference382RANCHO CUCAMONGA, CA / ACCESS Newswire / May 6, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations...
► Artikel lesen
30.04.Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7, 2026482RANCHO CUCAMONGA, CA / ACCESS Newswire / April 30, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that the Company will release results for its first quarter of 2026, ended March...
► Artikel lesen
06.04.Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Present at the 25th Annual Needham Healthcare Conference604RANCHO CUCAMONGA, CA / ACCESS Newswire / April 6, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") announced today that Bill Peters, CFO, Tony Marrs, EVP of Regulatory...
► Artikel lesen
04.03.Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Present at the Barclays 28th Annual Global Healthcare Conference604RANCHO CUCAMONGA, CA / ACCESS Newswire / March 4, 2026 / announced today that Bill Peters, CFO, and Dan Dischner, SVP of Corp. Communication, will be presenting at the Barclays 28th Annual Global Healthcare...
► Artikel lesen
26.02.Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2025858Net revenues of $183.1 million and $719.9 million, respectively, for the three months and fiscal year ended December 31, 2025GAAP net income of $24.4 million, or $0.51 per share and $98.1 million, or...
► Artikel lesen
24.02.Amphastar Pharmaceuticals, Inc.: Amphastar Announces FDA Approval for Ipratropium Bromide HFA833RANCHO CUCAMONGA, CA / ACCESS Newswire / February 24, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated...
► Artikel lesen
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1